Callan Capital, LLC Allogene Therapeutics, Inc. Transaction History
Callan Capital, LLC
- $1.2 Billion
- Q2 2024
A detailed history of Callan Capital, LLC transactions in Allogene Therapeutics, Inc. stock. As of the latest transaction made, Callan Capital, LLC holds 21,089 shares of ALLO stock, worth $61,368. This represents 0.0% of its overall portfolio holdings.
Number of Shares
21,089
Previous 21,089
-0.0%
Holding current value
$61,368
Previous $94,000
47.87%
% of portfolio
0.0%
Previous 0.01%
Shares
2 transactions
Others Institutions Holding ALLO
# of Institutions
176Shares Held
132MCall Options Held
94.3KPut Options Held
112K-
Tpg Gp A, LLC Fort Worth, TX18.7MShares$54.5 Million1.08% of portfolio
-
Black Rock Inc. New York, NY16.4MShares$47.9 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.2MShares$23.8 Million0.0% of portfolio
-
State Street Corp Boston, MA7.67MShares$22.3 Million0.0% of portfolio
-
Capital World Investors Los Angeles, CA6.9MShares$20.1 Million0.0% of portfolio
About Allogene Therapeutics, Inc.
- Ticker ALLO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 143,807,008
- Market Cap $418M
- Description
- Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...